Induction of diabetes by Streptozotocin in rats

被引：312

作者：

Akbarzadeh A. ^{[1
,4
]}

Norouzian D. ^{[1
]}

Mehrabi M.R. ^{[1
]}

Jamshidi Sh. ^{[1
]}

Farhangi A. ^{[1
]}

Allah Verdi A. ^{[1
]}

Mofidian S.M.A. ^{[2
]}

Lame Rad B. ^{[3
]}

机构：

[1] Department of Pilot Biotechnology, Pasteur Institute of Iran, Tehran

[2] Biometric Researcher, S.P. I. Institute, Karaj

[3] Biochemistry Department, Alzahra University, Tehran

[4] Department of Pilot Biotechnology, Tehran, 13164, 69-pasteur, Ave.

来源：

Indian Journal of Clinical Biochemistry | 2007年 / 22卷 / 2期

关键词：

Diabetes induction; Islet cells; Streptozotocin;

D O I：

10.1007/BF02913315

中图分类号：

学科分类号：

摘要：

The objective of this study is to induce experimental diabetes mellitus by Streptozotocin in normal adult Wistar rats via comparison of changes in body weight, consumption of food and water, volume of urine and levels of glucose, insulin and C- peptide in serum, between normal and diabetic rats. Intra-venous injection of 60mg/kg dose of Streptozotocin in adult wistar rats, makes pancreas swell and at last causes degeneration in Langerhans islet beta cells and induces experimental diabetes mellitus in the 2-4 days. Induction of experimental diabetes mellitus is indeed the first step in the plan of purification of pancreatic Langerhans islet cells of normal rats for transplanting under the testis subcutaneous of experimentally induced diabetic rats. Streptozotocin induces one type of diabetes which is similar to diabetes mellitus with non-ketosis hyperglycemia in some animal species. For induction of experimental diabetes in male adult rats weighted 250-300 grams (75-90 days), 60mg/kg of Streptozotocin was injected intravenously. Three days after degeneration of beta cells, diabetes was induced in all animals. The diabetic and normal animals were kept in the metabolic cages separately and their body weight, consumption of food and water, urine volume, the levels of serum glucose, insulin and C-peptide quantities in all animals were measured and then these quantities were compared. For a microscopic study of degeneration of Langerhans islet beta cells of diabetic rats, sampling from pancreas tissue of diabetic and normal rats, staining and comparison between them, were done. Induction of diabetes with Streptozotocin decreases Nicotinamide-adenine dinucleotide (NAD) in pancreas islet beta cells and causes histopathological effects in beta cells which probably intermediates induction of diabetes. In this study, we used Streptozotocin for our experiments in induction of experimental diabetes mellitus. After Induction of diabetes, consumption of food and water, volume of urine and glucose increased in the diabetic animals in comparison with normal animals, but the weight of body and the volume of insulin and C-peptide decreased in the diabetic animals. Sampling and staining of pancreas tissue of diabetic and normal rats showed that the Langerhans islet beta cells of diabetic rats have been clearly degenerated. In three days, Streptozotocin makes pancreas swell and at last causes degeneration in Langerhans islet beta cells and induces experimental diabetes. It also changes normal metabolism in diabetic rats in comparison with normal rats. Consumption of water and food, volume of urine, serum glucose increases in diabetic animals in comparison with normal rats but the levels of serum insulin, C-peptide and body weight decreases.

引用

页码：60 / 64

页数：4

共 11 条

[1]

World Health Organization

[2]

htt

[3]

Ikebukuro K., Adachi Y., Yamada Y., Fujimoto S., Seino Y., Oyaizu H., Treatment of Streptozotocin-induced diabetes mellitus by transplantation of islet cells Plus bone Marrow cells via portal vein in rats, Transplantation, 73, 4, pp. 512-518, (2002)

[4]

Rastellini C., Shapiro R., Corry R., Fung J.J., Starzl T.E., Rao A.S., An attempt to reverse diabetes by delayed islet cell transplantation in Humans, Transplantation proceedings, 29, pp. 2238-2239, (1997)

[5]

Elias D., Prigozin H., Polak N., Rapoport M., Lohse A.W., Cohen I.R., Autoimmune diabetes induced by the b - Cell toxin STZ, Diabetes, 43, pp. 992-998, (1994)

[6]

Weiss R.B., Streptozocin: A review of its pharmacology, efficacy and toxicity, Cancer Treatment Report 1982

[7]

Karunanayake E.H., Hearse D.J., Mellows G., The metabolic fate and elimination of streptozocin, Biochemical Society Transactions, 3, pp. 410-414, (1975)

[8]

Bhuyan B.K., Kuentzel S.L., Gray L.G., Wallach D., Neil G.L., Tissue distribution of streptozotocin (NSC 85998), Cancer Chemotherapy Report 1974

[9]

Levi J.A., Wiernik P.H., Diggs C.H., Combination chemotherapy of advanced Previously Treated Hodgkin's disease with streptozocin, CCNU, Adriamycin and bleomycin, Medical and pediatric oncology, 3, pp. 33-40, (1977)

[10]

Thulesen J., Qrskov C., Holst J.J., Poulsen S.S., Short Term Insulin Treatment Prevents the diabetogenic action of streptozotocin in rats, Endocrinology, 138, 1, pp. 62-68, (1997)

← 1 2 →